Want to see IN:MOREPENLAB full AI Analyst Report?
MOREPENLAB Stock Chart & Stats
₹41.99
-₹1.18(-1.56%)
At close: 4:00 PM EST
₹41.99
-₹1.18(-1.56%)
Day’s Range― - ―
52-Week Range₹33.42 - ₹66.36
Previous CloseN/A
Volume3.34M
Average Volume (3M)88.30K
Market Cap
₹32.32B
Enterprise Value₹29.60B
Total Cash (Recent Filing)₹932.86M
Total Debt (Recent Filing)₹1.58B
Price to Earnings (P/E)34.6
Beta1.83
Next Earnings
Jul 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.49%
Share Statistics
EPS (TTM)1.79
Shares Outstanding547,953,700
10 Day Avg. Volume126,704
30 Day Avg. Volume88,304
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)1.64
Price to Sales (P/S)1.13
P/FCF Ratio-14.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsMorepen’s mix of APIs, finished dosage formulations, and consumer healthcare products reduces single-market and single-customer concentration. This structural diversification supports revenue resilience, cross-selling, and multiple cash generation channels that remain relevant over a 2–6 month horizon.
Improved Profitability And MarginsReported recovery in earnings and healthier gross and operating margins through 2024–2026 suggests operational improvements and better cost or pricing dynamics. Sustained margin improvement supports longer-term profitability and operational durability if cash conversion can follow.
Manageable Leverage And Growing EquityA sizable and growing equity base with moderate leverage provides financial flexibility for working capital, capex, or R&D. This structural balance-sheet strength reduces short-term refinancing risk and helps absorb shocks, supporting strategic options over the coming months.
Bears Say
Weak Cash ConversionOperating cash flow remains small relative to reported earnings and free cash flow was negative for 2024–2026. Persistent negative FCF and volatile cash conversion constrain internal funding for growth or dividends, increase dependence on external financing, and raise sustainability concerns.
Rising Recent DebtA material increase in total debt in 2026 reduces balance-sheet flexibility and raises interest expense and refinancing risk. Higher leverage can pressure margins and limit the company’s ability to invest or respond to market shifts without further external funding.
Revenue And EPS ContractionDespite multi-year growth earlier, recent revenue decline and negative EPS growth indicate weakening top-line momentum and profitability pressure. Continued revenue contraction and margin compression undermine durable earnings power unless product demand or pricing recovers.
Morepen Laboratories Limited News
MOREPENLAB FAQ
What was Morepen Laboratories Limited’s price range in the past 12 months?
Morepen Laboratories Limited lowest stock price was ₹33.42 and its highest was ₹66.36 in the past 12 months.
What is Morepen Laboratories Limited’s market cap?
Morepen Laboratories Limited’s market cap is ₹32.32B.
When is Morepen Laboratories Limited’s upcoming earnings report date?
Morepen Laboratories Limited’s upcoming earnings report date is Jul 23, 2026 which is in 18 days.
How were Morepen Laboratories Limited’s earnings last quarter?
Morepen Laboratories Limited released its earnings results on May 26, 2026. The company reported ₹0.28 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.28.
Is Morepen Laboratories Limited overvalued?
According to Wall Street analysts Morepen Laboratories Limited’s price is currently Overvalued.
Does Morepen Laboratories Limited pay dividends?
Morepen Laboratories Limited pays a Annually dividend of ₹0.2 which represents an annual dividend yield of 0.49%. See more information on Morepen Laboratories Limited dividends here
What is Morepen Laboratories Limited’s EPS estimate?
Morepen Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Morepen Laboratories Limited have?
Morepen Laboratories Limited has 547,953,700 shares outstanding.
What happened to Morepen Laboratories Limited’s price movement after its last earnings report?
Morepen Laboratories Limited reported an EPS of ₹0.28 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.503%.
Which hedge fund is a major shareholder of Morepen Laboratories Limited?
Currently, no hedge funds are holding shares in IN:MOREPENLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Morepen Laboratories Limited
Morepen Laboratories Limited is an Indian pharmaceutical company primarily engaged in the development, manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs), proprietary and generic pharmaceutical formulations, and a diverse range of home healthcare products. Its API portfolio encompasses compounds utilized in the creation of drugs for conditions such as allergies, asthma, elevated cholesterol, hypertension, and diabetes. The company also supplies an array of point-of-care and medical devices for home use, including diagnostic tools like air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse oximeters, nebulizers, glucometers with accompanying strips, as well as hygiene products such as sanitizers, disinfectant solutions, masks, and gloves. Among its well-known branded products are Burnol, a cream for treating burns; Lemolate, an offering for cough and cold relief; and Fiber-X, a psyllium husk supplement. Furthermore, Morepen produces finished drug formulations covering various therapeutic areas, including gastrointestinal health, antibiotics, vitamins, nutritional support, anti-diabetics, and cardiovascular conditions. Beyond these offerings, the company undertakes contract manufacturing for other businesses and participates in brand sharing agreements. Its comprehensive range of over-the-counter (OTC) products is marketed under the recognizable Dr. Morepen brand. The company's global footprint extends to approximately 75 nations, where its products are exported. Established in 1984, Morepen Laboratories Limited maintains its headquarters in New Delhi, India.
Technical Analysis
Alembic Limited
―
Hikal Limited
―
Indoco Remedies Limited
―
Solara Active Pharma Sciences Ltd.
―
Windlas Biotech Ltd.
―





